Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aquestive Therapeutics ( (AQST) ) has issued an update.
On June 11, 2025, Aquestive Therapeutics, Inc. held its Annual Meeting of Stockholders, where key decisions were made. Daniel Barber and Timothy E. Morris were elected as Class I members of the Board of Directors for a three-year term. Additionally, the stockholders approved executive compensation on a non-binding advisory basis and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Aquestive Therapeutics currently faces significant financial and operational challenges. The most critical risk factors include declining revenues, negative profit margins, and high leverage. While technical indicators show potential short-term momentum, valuation metrics and corporate events reveal underlying financial difficulties that hinder long-term prospects.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative products to address unmet medical needs.
Average Trading Volume: 1,512,563
Technical Sentiment Signal: Strong Buy
Current Market Cap: $355.6M
For a thorough assessment of AQST stock, go to TipRanks’ Stock Analysis page.